首页> 美国卫生研究院文献>Oncotarget >The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer

【2h】

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer

机译：ERBB家族种系单核苷酸多态性对HER2阳性乳腺癌患者曲妥珠单抗辅助治疗生存应答的影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

BackgroundTrastuzumab treatment for women with HER2-positive breast cancer (BC) resulted in the significant improvement of both relapse free survival (RFS) and overall survival (OS). However, many women who are classified as HER2-positive do not respond. Many studies have focused on the role of somatic mutations rather than germline polymorphisms in trastuzumab resistance.

机译：背景：曲妥珠单抗治疗HER2阳性乳腺癌（BC）的妇女可显着改善无复发生存期（RFS）和总体生存期（OS）。但是，许多被归类为HER2阳性的女性没有反应。许多研究聚焦于体细胞突变而不是种系多态性在曲妥珠单抗中的作用。

著录项

期刊名称 Oncotarget
作者
Sinead Toomey; Stephen F. Madden; Simon J. Furney; Yue Fan; Mark McCormack; Carragh Stapleton; Mattia Cremona; Gianpiero L. Cavalleri; Malgorzata Milewska; Naomi Elster; Aoife Carr; Joanna Fay; Elaine W. Kay; Susan Kennedy; John Crown; William M. Gallagher; Bryan T. Hennessy; Alex J. Eustace;
展开▼
作者单位

展开▼
年(卷),期 2016(7),46
年度 2016
页码 75518–75525
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学;细胞生物学;
关键词
ERBB-family germline mutations single nucleotide polymorphisms high depth sequencing survival impact;

机译：ERBB家族种系突变;单核苷酸多态性;高深度测序;生存影响;

相似文献

外文文献
中文文献
专利

1. 曲妥珠单抗对30例Her2阳性中国乳腺癌患者术后辅助治疗安全性的初步观察 [J] . 周宁宁, 滕小玉, 刘冬耕, 癌症（英文版） . 2008,第012期
2. HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up [J] . Jackisch Christian, Hegg Roberto, Stroyakovskiy Daniil, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：HannaH III期随机研究：经过2年无治疗随访的新辅助-辅助曲妥珠单抗治疗的HER2阳性早期乳腺癌的总病理学完全缓解与无事件生存的相关性
3. A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results [J] . Pivot X., Bondarenko I., Nowecki Z., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：将SB3（拟议的Trastuzumab BioSimilar）和Trastuzumab参考产物与Neoadjuvant辅助治疗治疗的Her2阳性早期乳腺癌中的第III期研究：最终安全性，免疫原性和生存结果
4. FcrR3A-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment [J] . Chae Heejung, Yoo Changhoon, Yoon Jung-A, Journal of Breast Cancer . 2018,第1期

机译：接受曲妥珠单抗治疗的转移性HER2阳性乳腺癌患者中FcrR3A-158的多态性和间质瘤浸润淋巴细胞的生存率
5. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
6. Gut Microbiota and Trastuzumab Response in HER2-Positive Breast Cancer [D] . Di Modica, Martina. 2020

机译：肠道微生物群和胸瘤反应在Her2阳性乳腺癌中
7. Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH) [O] . Damien Coté, Alex Eustace, Sinead Toomey, 2012

机译：ERBB3和BARD1基因中的生殖细胞单核苷酸多态性导致以多西他赛，卡铂和曲妥珠单抗（TCH）为佐剂的HER2阳性乳腺癌患者的无复发生存应答更差
8. HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up [O] . Jackisch Christian, Hegg Roberto, Stroyakovskiy Daniil, 2016

机译：HannaH III期随机研究：经过2年的无治疗随访后，新辅助药物联合曲妥珠单抗治疗的HER2阳性早期乳腺癌的总病理学完全缓解与无事件生存的相关性

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅